A Randomized, Double-blind, Placebo-controlled Phase Ib Multiple-ascending Dose trial of APD 334 in Healthy Subjects

Trial Profile

A Randomized, Double-blind, Placebo-controlled Phase Ib Multiple-ascending Dose trial of APD 334 in Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Jan 2015

At a glance

  • Drugs Etrasimod (Primary)
  • Indications Autoimmune disorders; Multiple sclerosis; Psoriasis; Rheumatoid arthritis
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Arena Pharmaceuticals
  • Most Recent Events

    • 07 Jan 2015 Top-line results published in an Arena Pharmaceuticals media release.
    • 03 Jun 2014 Status changed from planning to recruiting according to the Arena Pharmaceuticals media release.
    • 06 Mar 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top